EA201491452A1 - Антитела к asic1 и их применение - Google Patents

Антитела к asic1 и их применение

Info

Publication number
EA201491452A1
EA201491452A1 EA201491452A EA201491452A EA201491452A1 EA 201491452 A1 EA201491452 A1 EA 201491452A1 EA 201491452 A EA201491452 A EA 201491452A EA 201491452 A EA201491452 A EA 201491452A EA 201491452 A1 EA201491452 A1 EA 201491452A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
asic1
present
cells expressing
application
Prior art date
Application number
EA201491452A
Other languages
English (en)
Other versions
EA028647B1 (ru
Inventor
Линн МАКДОНАЛЬД
Мин Гао
Марк Р. Морра
Николь М. Аллесандри-Хабер
Мишель Л. Лакруа-Фралиш
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201491452(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201491452A1 publication Critical patent/EA201491452A1/ru
Publication of EA028647B1 publication Critical patent/EA028647B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Abstract

Настоящее изобретение предлагает антитела и их антигенсвязывающие фрагменты, которые специфически связываются с клетками, экспрессирующими кислоточувствительный ионный канал 1 (ASIC1). В соответствии с некоторыми вариантами осуществления настоящего изобретения антитела ингибируют индуцируемые кислотами ASICl-опосредованные ионные токи в клетках, экспрессирующих человеческие ASIC1. Антитела настоящего изобретения применяются для лечения боли, включая боль, связанную с хирургическим вмешательством, различными заболеваниями и нарушениями.
EA201491452A 2012-01-31 2013-01-30 Антитела к asic1 и их применение EA028647B1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US61/592,837 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US61/644,038 2012-05-08
US201261692925P 2012-08-24 2012-08-24
US61/692,925 2012-08-24
PCT/US2013/023784 WO2013116296A1 (en) 2012-01-31 2013-01-30 Anti-asic1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
EA201491452A1 true EA201491452A1 (ru) 2014-11-28
EA028647B1 EA028647B1 (ru) 2017-12-29

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491452A EA028647B1 (ru) 2012-01-31 2013-01-30 Антитела к asic1 и их применение

Country Status (33)

Country Link
US (3) US9150648B2 (ru)
EP (2) EP3453723B1 (ru)
JP (1) JP6302844B2 (ru)
KR (1) KR102111941B1 (ru)
CN (1) CN104093738B (ru)
AR (1) AR089852A1 (ru)
AU (1) AU2013215254B2 (ru)
CA (1) CA2862332C (ru)
CL (1) CL2014002019A1 (ru)
CO (1) CO7020877A2 (ru)
CY (2) CY1121368T1 (ru)
DK (2) DK2809681T3 (ru)
EA (1) EA028647B1 (ru)
ES (2) ES2707599T3 (ru)
HK (1) HK1199269A1 (ru)
HR (2) HRP20211541T1 (ru)
HU (2) HUE042531T2 (ru)
IL (2) IL233410A0 (ru)
IN (1) IN2014CN04645A (ru)
JO (1) JO3547B1 (ru)
LT (2) LT2809681T (ru)
MX (1) MX358518B (ru)
MY (1) MY168748A (ru)
NZ (1) NZ626242A (ru)
PH (1) PH12014501613A1 (ru)
PL (2) PL3453723T3 (ru)
PT (2) PT3453723T (ru)
RS (2) RS62454B1 (ru)
SG (1) SG11201403222UA (ru)
SI (2) SI2809681T1 (ru)
TW (1) TWI591073B (ru)
UY (1) UY34603A (ru)
WO (1) WO2013116296A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2809681T (lt) 2012-01-31 2019-02-11 Regeneron Pharmaceuticals, Inc. Antikūnai prieš asic1 ir jų panaudojimas
MA39847A (fr) 2014-04-15 2017-02-22 Sorrento Therapeutics Inc Protéines de liaison à l'antigène se liant à wisp1
KR20230145503A (ko) 2014-05-16 2023-10-17 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
SI3143042T1 (sl) * 2014-05-16 2020-08-31 Ablynx N.V. Variabilne domene imunoglobulina
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
US10941213B2 (en) * 2018-01-26 2021-03-09 Regeneron Pharmaceuticals, Inc. Anti-TMPRSS2 antibodies and antigen-binding fragments
CN114729034B (zh) * 2019-06-04 2024-01-12 上海科技大学 亲和力成熟的抗ASIC1a抗体
CA3146566A1 (en) * 2019-07-11 2021-01-14 Memorial Sloan Kettering Cancer Center Dll3-targeting antibodies and uses thereof
US20230287107A1 (en) * 2019-07-23 2023-09-14 Shanghaitech University Asic1 channel antagonist antibody
WO2021050857A1 (en) * 2019-09-13 2021-03-18 Memorial Sloan-Kettering Cancer Center Anti-cd371 antibodies and uses thereof
WO2023019121A2 (en) * 2021-08-09 2023-02-16 Merck Patent Gmbh Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
WO2023034566A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-dll3 antibodies and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
ES2279583T3 (es) 1997-10-29 2007-08-16 Mcgill University Adn que codifica para un canal ionico regulado por protones humano y usos del mismo.
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) * 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
WO2003085089A2 (en) * 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
EP1667735A2 (en) * 2003-09-11 2006-06-14 The Uab Research Foundation Inhibition of inward sodium currents in cancer
WO2005074923A1 (en) 2004-02-03 2005-08-18 Agt Biosciences Limited Methods and compositions
JP2007530664A (ja) 2004-03-30 2007-11-01 ペインセプター ファーマ コーポレーション ゲートイオンチャンネルを調節するための組成物及び方法
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
AU2005319382B2 (en) * 2004-12-21 2011-04-07 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
AU2006238930B2 (en) * 2005-04-26 2010-12-23 Pfizer Inc. P-cadherin antibodies
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
EP2078732B1 (en) * 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
US8618113B2 (en) 2006-07-14 2013-12-31 Medical Research Council Treatment for demyelinating disease
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
DK2137539T3 (da) 2007-04-03 2011-01-24 Ilegusavnid Genetics Resource Ct Minestry Of Social Affairs And Health Amolorid følsomme calciumkanaler forbundet med paniklidelser
CA2683145C (en) * 2007-04-27 2018-06-12 Katherine E. Lewis Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2288922B1 (en) * 2008-05-08 2016-08-17 University of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
WO2010054007A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
LT2809681T (lt) 2012-01-31 2019-02-11 Regeneron Pharmaceuticals, Inc. Antikūnai prieš asic1 ir jų panaudojimas

Also Published As

Publication number Publication date
MX2014008541A (es) 2014-10-24
AR089852A1 (es) 2014-09-24
CA2862332C (en) 2021-05-18
US20130195878A1 (en) 2013-08-01
PL3453723T3 (pl) 2022-01-03
CY1121368T1 (el) 2020-05-29
RS58439B1 (sr) 2019-04-30
CO7020877A2 (es) 2014-08-11
EA028647B1 (ru) 2017-12-29
IL233410A0 (en) 2014-08-31
PL2809681T3 (pl) 2019-05-31
MX358518B (es) 2018-08-24
EP2809681B1 (en) 2018-12-05
CN104093738A (zh) 2014-10-08
SI2809681T1 (sl) 2019-04-30
PH12014501613B1 (en) 2014-10-13
HUE056335T2 (hu) 2022-02-28
CY1124778T1 (el) 2022-11-25
PH12014501613A1 (en) 2014-10-13
RS62454B1 (sr) 2021-11-30
PT3453723T (pt) 2021-09-07
CA2862332A1 (en) 2013-08-08
IL254416B (en) 2018-03-29
HRP20190358T1 (hr) 2019-04-05
TWI591073B (zh) 2017-07-11
UY34603A (es) 2013-07-31
LT2809681T (lt) 2019-02-11
CN104093738B (zh) 2018-05-18
US20180222976A1 (en) 2018-08-09
PT2809681T (pt) 2019-02-18
WO2013116296A1 (en) 2013-08-08
SG11201403222UA (en) 2014-07-30
TW201335182A (zh) 2013-09-01
EP3453723A2 (en) 2019-03-13
DK2809681T3 (en) 2019-03-11
DK3453723T3 (da) 2021-09-13
CL2014002019A1 (es) 2015-01-16
US10513557B2 (en) 2019-12-24
US20160002332A1 (en) 2016-01-07
KR102111941B1 (ko) 2020-05-18
KR20140125363A (ko) 2014-10-28
ES2886123T3 (es) 2021-12-16
HUE042531T2 (hu) 2019-07-29
JP6302844B2 (ja) 2018-03-28
JO3547B1 (ar) 2020-07-05
MY168748A (en) 2018-11-30
HK1199269A1 (en) 2015-06-26
ES2707599T3 (es) 2019-04-04
IN2014CN04645A (ru) 2015-09-18
LT3453723T (lt) 2021-09-10
BR112014018651A2 (pt) 2017-07-04
US9150648B2 (en) 2015-10-06
SI3453723T1 (sl) 2021-11-30
EP3453723B1 (en) 2021-08-11
JP2015508063A (ja) 2015-03-16
IL254416A0 (en) 2017-11-30
AU2013215254A1 (en) 2014-07-03
EP3453723A3 (en) 2019-04-10
EP2809681A1 (en) 2014-12-10
HRP20211541T1 (hr) 2021-12-24
AU2013215254B2 (en) 2017-08-31
NZ626242A (en) 2017-02-24

Similar Documents

Publication Publication Date Title
EA201491452A1 (ru) Антитела к asic1 и их применение
CY1123256T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
EA201591762A1 (ru) Человеческие антитела к grem1
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
MX2015010749A (es) Anticuerpos humanos para nav1.7.
MY185813A (en) Factor xi antibodies and methods of use
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA201590085A1 (ru) Антитела анти-egfr и их применение
BR112018068678A2 (pt) anticorpos anti-mica
EA201590144A1 (ru) Rspo3-связывающие агенты и их применение
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
WO2015009726A3 (en) Medical uses of cd38 agonists
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
EA201592203A1 (ru) Способы лечения таупатии
EA201690503A1 (ru) Антитела
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
MX2015017853A (es) Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso.
PH12015502829A1 (en) Lectin-like oxidized ldl receptor1 antibodies and methods of use
EA201691220A1 (ru) Способ для получения композиции пегилированных белков
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.
MA35863B1 (fr) Anticorps anti-asic1 et leurs utilisations

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM